Key Program Features

  • Small-molecule, host directed compounds
  • Orally bioavailable immuno-therapy
  • Target RIG-I-like receptor (RLR) pathways and intracellular IRF3-inducing pathways
  • May facilitate tumor cell killing and break cancer tolerance

Immuno-oncology

Drug Development Phase: Discovery (Lead Optimization)

Kineta’s scientists have identified novel small-molecule compounds that target RIG-I-like receptor (RLR) pathways and intracellular IRF3-inducing pathways. Kineta's approach is to develop immuno-therapies focused on these drug targets for applications in cancer. Kineta’s host directed RLR agonists induce key markers of immunogenic cell death (ICD). Furthermore, Kineta’s RLR agonists may break tumor tolerance, elicit neo-antigen T-cell responses and may turn the "cold" tumor "hot". They are being developed as small-molecule, orally bioavailable immuno-therapies for solid tumors.